Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease – analysis of institutional and population data-Reference-Cited by-同舟云学术

Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease – analysis of institutional and population data

Published:2018-10-03 Issue:1 Volume:19 Page:
ISSN:1465-993X
Container-title:Respiratory Research
language:en
Short-container-title:Respir Res

Author:

Yoon Joo Heung^ORCID,Nouraie Mehdi,Chen Xiaoping,Zou Richard H,Sellares Jacobo,Veraldi Kristen L,Chiarchiaro Jared,Lindell Kathleen,Wilson David O,Kaminski Naftali,Burns Timothy,Trejo Bittar Humberto,Yousem Samuel,Gibson Kevin,Kass Daniel J

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s12931-018-0899-4.pdf

Reference41 articles.

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ, Fibrosis AEJACIP. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.

2. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol. 2013;5:483–92.

3. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, Group AS. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–92.

4. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR, Investigators IT. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.

5. Wuyts WA, Cavazza A, Rossi G, Bonella F, Sverzellati N, Spagnolo P. Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic? Eur Respir Rev. 2014;23:308–19.

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of lung cancer occurring in fibrotic versus non-fibrotic lung on chest CT;Journal of Translational Medicine;2024-01-16

2. Combining single-cell RNA sequencing data and transcriptomic data to unravel potential mechanisms and signature genes of the progression of idiopathic pulmonary fibrosis to lung adenocarcinoma and predict therapeutic agents;Functional & Integrative Genomics;2023-11-24

3. Lung Cancer in Never Smokers: Delving into Epidemiology, Genomic and Immune Landscape, Prognosis, Treatment, and Screening;Lung;2023-11-16

4. T cell immunity in interstitial lung disease with non-small cell lung cancer patients;Lung Cancer;2023-08

5. Management of patients with idiopathic pulmonary fibrosis and lung cancer: challenges in clinical practice;Current Opinion in Pulmonary Medicine;2023-06-28